<DOC>
	<DOCNO>NCT00800150</DOCNO>
	<brief_summary>RATIONALE : Giving total marrow total lymph node irradiation together low dos chemotherapy donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . PURPOSE : This phase I trial study side effect best dose total marrow total lymph node irradiation give together fludarabine melphalan follow donor stem cell transplant treat patient advanced hematological cancer respond treatment .</brief_summary>
	<brief_title>Total Marrow Total Lymph Node Irradiation , Fludarabine , Melphalan Followed By Donor Stem Cell Transplant Treating Patients With Advanced Hematological Cancer That Has Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose intensity-modulated total marrow lymph node irradiation ( TMLI ) use helical tomotherapy combination reduced-intensity preparative regimen comprise fludarabine phosphate melphalan patient undergo allogeneic hematopoietic stem cell transplantation advance , relapse refractory hematological malignancy . - To describe toxicity escalate dos TMLI patient . Secondary - To describe frequency clinical response patient treat regimen . - To describe frequency primary secondary engraftment failure patient treat regimen . - To describe time neutrophil platelet engraftment patient treat regimen . - To describe incidence acute chronic graft-versus-host disease patient treat regimen . - To describe overall survival patient treat regimen . - To describe progression-free survival patient treat regimen . OUTLINE : This dose-escalation study intensity-modulated total marrow lymph node irradiation ( TMLI ) . - Intensity-modulated radiation therapy : Patients undergo TMLI skeletal bone/marrow , major lymph node chain , spleen , liver use helical tomotherapy twice daily day -6 -3 . - Reduced-intensity preparative regimen : Patients receive fludarabine phosphate IV day -6 -2 melphalan IV day -1 . - Hematopoietic stem cell transplantation ( HSCT ) : Patients undergo allogeneic HSCT day 0 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm diagnosis 1 following : Acute myeloid leukemia ( AML ) Myelodysplastic syndrome Intermediate highrisk disease Myelofibrosis Granulocytic sarcoma ( chloroma ) With without bone marrow involvement Mixed lineage leukemia Induction therapy must direct predominantly AML Acute lymphoblastic leukemia NonHodgkin lymphoma Multiple myeloma Relapsed refractory disease M3 marrow ( marrow blast &gt; 25 % ) , meet 1 follow criterion : Persistent disease induction attempt Persistent initial disease two induction attempt Relapse one reinduction attempt ( second relapse ) Persistent disease first relapse initial reinduction attempt Not eligible myeloablative allogeneic hematopoietic stem cell transplantation due age ( &gt; 50 year ) , organ insufficiency , significant comorbidity Patients 1650 year age must meet ≥ 1 follow criterion : Ejection fraction 5060 % MUGA scan and/or echocardiogram DLCO 5075 % predict Creatinine clearance GFR 6080 mL/min Serum bilirubin ≤ 2.0 mg/dL SGOT SGPT 1.55 time upper limit normal No medical and/or psychosocial problem , opinion primary physician principal investigator , would place patient unacceptable risk study regimen No Fanconi anemia HLAidentical sibling OR match unrelated donor available PATIENT CHARACTERISTICS : Zubrod Karnofsky performance status 70100 % Negative pregnancy test Able lie supine full body cast 30 minute No HIV infection No evidence active hepatitis B C infection No evidence cirrhosis No uncontrolled viral , bacterial , fungal infection within past 4 week No radiographic change indicate pulmonary disease ( e.g. , pulmonary nodule , infiltrates , pleural effusion ) unless clear pulmonary biopsy show evidence active pulmonary disease No major medical psychiatric disorder would seriously compromise patient tolerance study regimen PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
</DOC>